Coordinating center for the NCI small cell lung cancer research consortium

NCI 小细胞肺癌研究联盟协调中心

• 批准号: 10653236
• 负责人: Lauren Averett Byers
• 金额: $ 156.55万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-06-24 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10653236
• 关键词: Address; Administrative Coordination; Advocate; Area; Award; Bioinformatics; Biological; Biological Specimen database; Biometry; Cancer Model; Cataloging; Clinical; Clinical Trials; Collaborations; Collection; Communication; Communities; Complement; Congresses; Data; Data Analyses; Data Analytics; Databases; Development; Disease; Disease model; Early Diagnosis; Early Intervention; Epigenetic Process; Fostering; Funding; Funding Opportunities; Generations; Genetic Databases; Genetically Engineered Mouse; Goals; Grant; Growth; Health; Human; Immunologic Surveillance; Immunologics; Individual; Institution; Intervention; Knowledge; Leadership; Maintenance; Malignant Neoplasms; Metastasis Suppression; Modeling; Molecular and Cellular Biology; Mus; Oncogenic; Pathology; Patient-Focused Outcomes; Patients; Peer Review; Prevention; Prevention strategy; Principal Investigator; Proteomics; Publications; Research; Research Personnel; Resource Sharing; Resources; Role; Rotation; Secure; Societies; Structure; Sum; Teleconferences; Therapeutic; Therapeutic Research; Translational trial; Universities; University of Texas M D Anderson Cancer Center; Utah; Work; anticancer research; cancer immunotherapy; central database; clinical translation; cohort; comparative; design; disorder prevention; improved; in vitro Model; in vivo; innovation; insight; meetings; member; novel strategies; novel therapeutics; patient derived xenograft model; pre-clinical; repository; small cell lung carcinoma; success; synergism; tissue resource; transcriptomics; tumor; virtual; web site

ABSTRACT The overarching goal of the NCI Small Cell Lung Cancer (SCLC) Coordinating Center has been to “break the logjam” of fundamental knowledge gaps resulting in a 30+ year lack of progress on this lethal malignancy that was designated a “recalcitrant cancer” by the US Congress and NCI. Our U24 Coordinating Center has done this by promoting and facilitating information sharing, interaction, and collaborative research among NCI- supported investigators studying SCLC. Over our initial five years of support, this Coordinating Center has significantly increased research progress within the SCLC research community through efforts including, but not limited to, the creation and ongoing expansion of comprehensive preclinical and clinical -omics databases, centralized annotation and cataloging of available SCLC models, distribution and sharing of such models, centralized data analytics, a centralized Consortium website, initiation and coordination of an interactive work- in-progress (“WIPs”) forum as well as planning and oversight of annual meetings. Of all of this, the role of the Coordinating Center in facilitating interactive WIPs (usually with ~100 attendees from dozens of institutions including patient advocates) with unprecedented information and resource sharing, has made possible tremendous progress in overcoming knowledge gaps, all of which are documented in a large number of peer reviewed publications. This renewal application will continue the exceptional research momentum the SCLC Consortium has generated, and build on this initial success through support of new initiatives. These include centralized support for databasing and comparative analysis of genetically-engineered mouse models (GEMMs), and multi-parameter characterization of patient-derived xenograft models developed across the Consortium. These additional resources will be of direct utility to the SCLC research community. As part of the U24 renewal, given the remarkable growth in scope and diversity of SCLC research, we have developed a new multi-PI structure including Charles Rudin (MSK), John Minna (UTSW), with addition of two exciting young SCLC investigators who have contributed important new insights into SCLC molecular and cellular biology - Trudy Oliver (University of Utah), and Lauren Byers (MDACC). All four have been personally very active both in the U24 activities and in their own individual SCLC U01 and R01 research. The complementary strengths of this leadership team cover all of the important areas of SCLC basic, translational, and clinical trials research. Dr. Rudin will continue as contact PI, providing administrative leadership and coordination. We emphasize that the products of the Consortium will ultimately benefit human health through fostering development of novel strategies for disease prevention, early intervention, immune surveillance, metastasis suppression, and therapeutics.

抽象的 NCI 小细胞肺癌 (SCLC) 协调中心的总体目标是“打破 基础知识差距的“僵局”导致 30 多年来在这种致命恶性肿瘤方面缺乏进展 被美国国会和 NCI 指定为“顽固性癌症”。我们的U24协调中心已经做了 通过促进和促进 NCI 之间的信息共享、互动和协作研究， 支持研究 SCLC 的研究人员。在我们最初五年的支持中，该协调中心已经 通过以下努力显着提高了 SCLC 研究界的研究进展，但不包括 仅限于创建和持续扩展综合性临床前和临床组学数据库， 可用 SCLC 模型的集中注释和编目，此类模型的分发和共享， 集中式数据分析、集中式联盟网站、交互式工作的发起和协调 正在进行的（“WIP”）论坛以及年度会议的规划和监督。在所有这一切中， 促进互动 WIP 的协调中心（通常有来自数十个机构的约 100 名与会者） 包括患者倡导者）通过前所未有的信息和资源共享，使 在克服知识差距方面取得了巨大进展，所有这些都记录在大量同行中 审查出版物。此次更新申请将延续 SCLC 的卓越研究势头 联盟通过支持新举措，取得了初步成功，并在此基础上再接再厉。这些包括 集中支持基因工程小鼠模型（GEMM）的数据库和比较分析， 以及整个联盟开发的患者来源的异种移植模型的多参数表征。 这些额外资源将对 SCLC 研究界直接有用。作为U24续约的一部分， 鉴于 SCLC 研究范围和多样性的显着增长，我们开发了一种新的多 PI 结构包括 Charles Rudin (MSK)、John Minna (UTSW)，另外还增加了两名令人兴奋的年轻 SCLC 对 SCLC 分子和细胞生物学贡献重要新见解的研究人员 - Trudy 奥利弗（犹他大学）和劳伦·拜尔斯（MDACC）。所有四人个人都非常活跃 U24 活动以及他们自己的个人 SCLC U01 和 R01 研究。双方优势互补 领导团队涵盖SCLC基础、转化和临床试验研究的所有重要领域。博士。 Rudin 将继续担任联络 PI，提供行政领导和协调。我们强调， 该联盟的产品将通过促进新战略的发展最终造福人类健康 用于疾病预防、早期干预、免疫监视、抑制转移和治疗。

项目成果

Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation.

• DOI: 10.1158/2159-8290.cd-20-1863
• 发表时间: 2021-12-01
• 期刊: CANCER DISCOVERY
• 影响因子: 28.2
• 作者: Quintanal-Villalonga, Alvaro;Taniguchi, Hirokazu;Zhan, Yingqian A.;Hasan, Maysun M.;Chavan, Shweta S.;Meng, Fanli;Uddin, Fathema;Manoj, Parvathy;Donoghue, Mark T. A.;Won, Helen H.;Chan, Joseph M.;Ciampricotti, Metamia;Chow, Andrew;Offin, Michael;Chang, Jason C.;Ray-Kirton, Jordana;Tischfield, Sam E.;Egger, Jacklynn, V;Bhanot, Umesh K.;Linkov, Irina;Asher, Marina;Sinha, Sonali;Silber, Joachim;Iacobuzio-Donahue, Christine A.;Roehrl, Michael H.;Hollmann, Travis J.;Yu, Helena A.;Qiu, Juan;de Stanchina, Elisa;Baine, Marina K.;Rekhtman, Natasha;Poirier, John T.;Loomis, Brian;Koche, Richard P.;Rudin, Charles M.;Sen, Triparna
• 通讯作者: Sen, Triparna

Protocol to dissociate, process, and analyze the human lung tissue using single-cell RNA-seq.

• DOI: 10.1016/j.xpro.2022.101776
• 发表时间: 2022-12-16
• 期刊: STAR protocols
• 作者: Quintanal-Villalonga Á;Chan JM;Masilionis I;Gao VR;Xie Y;Allaj V;Chow A;Poirier JT;Pe'er D;Rudin CM;Mazutis L
• 通讯作者: Mazutis L

POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC.

• DOI: 10.1016/j.jtho.2022.06.004
• 发表时间: 2022-09
• 期刊: JOURNAL OF THORACIC ONCOLOGY
• 影响因子: 20.4
• 作者: Baine, Marina K.;Febres-Aldana, Christopher A.;Chang, Jason C.;Jungbluth, Achim A.;Sethi, Shenon;Antonescu, Cristina R.;Travis, William D.;Hsieh, Min-Shu;Roh, Mee Sook;Homer, Robert J.;Ladanyi, Marc;Egger, Jacklynn V.;Lai, W. Victoria;Rudin, Charles M.;Rekhtman, Natasha
• 通讯作者: Rekhtman, Natasha

Small-cell lung cancer.

• DOI: 10.1038/s41572-020-00235-0
• 发表时间: 2021-01-14
• 期刊: Nature reviews. Disease primers
• 作者: Rudin CM;Brambilla E;Faivre-Finn C;Sage J
• 通讯作者: Sage J

Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.

• DOI: 10.1186/s13045-023-01464-y
• 发表时间: 2023-06-24
• 期刊: JOURNAL OF HEMATOLOGY & ONCOLOGY
• 影响因子: 28.5
• 作者: Rudin, Charles M. M.;Reck, Martin;Johnson, Melissa L. L.;Blackhall, Fiona;Hann, Christine L. L.;Yang, James Chih-Hsin;Bailis, Julie M. M.;Bebb, Gwyn;Goldrick, Amanda;Umejiego, John;Paz-Ares, Luis
• 通讯作者: Paz-Ares, Luis